HOME » News & Media

    Vyome Bio's Acne Drug IND Application Gets US FDA Nod


    14th Jan 2016. Bio-pharmaceutical company Vyome Biosciences today said the US Food and Drug Administration (USFDA) has cleared its investigational new drug (IND) to treat moderate-to-severe acne. 

    "We have received USFDA acceptance of Investigational New Drug application in the US for our lead product VB-1953 to treat moderate-to-severe acne. We plan to start Phase-I clinical trials very soon," a company statement said here. 

    "With US FDA accepting our first IND application for the lead 
    program VB-1953, we have become a clinical stage company in US, which is an important value inflection milestone for us. 

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.